Poxel Provides Corporate Update and Reports Cash and Revenue for the Third Quarter and Nine Months 2023
Sumitomo Pharma has worked diligently to increase the production and secure inventory capacity to meet this increasing demand.
- Sumitomo Pharma has worked diligently to increase the production and secure inventory capacity to meet this increasing demand.
- For the Sumitomo Pharma FY 2023, as a conservative assumption in line with Sumitomo Pharma’s forecast, Poxel expects to receive 8% royalties on TWYMEEG net sales.
- On July 5th, Poxel was chosen as the winner of the 2023 edition of the I-nov contest for its program in ALD.
- Next Financial Press Release: Fourth Quarter 2023 Cash and Revenue update, on February 15, 2024